Search Results - "LEWIS, Nancy L"

Phase I Pharmacologic and Biologic Study of Ramucirumab (IMC-1121B), a Fully Human Immunoglobulin G1 Monoclonal Antibody Targeting the Vascular Endothelial Growth Factor Receptor-2 by SPRATLIN, Jennifer L, COHEN, Roger B, MEROPOL, Neal J, LEWIS, Nancy L, CHIOREAN, E. Gabriela, FOX, Floyd, YOUSSOUFIAN, Hagop, ROWINSKY, Eric K, GAIL ECKHARDT, S, EADENS, Matthew, GORE, Lia, CAMIDGE, D. Ross, DIAB, Sami, LEONG, Stephen, O'BRYANT, Cindy, CHOW, Laura Q. M, SERKOVA, Natalie J

“…PURPOSE To evaluate the safety, maximum-tolerated dose (MTD), pharmacokinetics (PKs), pharmacodynamics, and preliminary anticancer activity of ramucirumab…”
Get full text

Effects of Food on the Relative Bioavailability of Lapatinib in Cancer Patients by KOCH, Kevin M, REDDY, Nandi J, COHEN, Roger B, LEWIS, Nancy L, WHITEHEAD, Bonnie, MACKAY, Kathleen, STEAD, Andrew, BEELEN, Andrew P, LEWIS, Lionel D

“…This study was conducted to characterize the effect of food on the relative bioavailability of lapatinib. A single 1,500-mg, oral dose of lapatinib was…”
Get full text

Phase I Study of the Safety, Tolerability, and Pharmacokinetics of Oral CP-868,596, a Highly Specific Platelet-Derived Growth Factor Receptor Tyrosine Kinase Inhibitor in Patients With Advanced Cancers by Lewis, Nancy L, Lewis, Lionel D, Eder, Joseph P, Reddy, Nandi J, Guo, Feng, Pierce, Kristen J, Olszanski, Anthony J, Cohen, Roger B

“…This phase I, first-in-human study evaluated the safety, tolerability, pharmacokinetics, and maximum-tolerated dose (MTD) of an oral platelet-derived growth…”
Get full text

Phase II and Pharmacodynamic Study of the Farnesyltransferase Inhibitor R115777 as Initial Therapy in Patients With Metastatic Pancreatic Adenocarcinoma by COHEN, Steven J, HO, Linus, THISTLE, Amanda M, VERHAEGHE, Tom, HAO WANG, WEINER, Louis M, WRIGHT, John J, HUDES, Gary R, MEROPOL, Neal J, RANGANATHAN, Sulabha, ABBRUZZESE, James L, ALPAUGH, R. Katherine, BEARD, Mary, LEWIS, Nancy L, MCLAUGHLIN, Susan, ROGATKO, André, PEREZ-RUIXO, Juan J

“…R115777 is a selective nonpeptidomimetic inhibitor of farnesyltransferase (FTase), one of several enzymes responsible for posttranslational modification that…”
Get full text

The Effect of Stretching on Muscle Responses and Postural Sway Responses During Computerized Dynamic Posturography in Women and Men by Lewis, Nancy L., ScD, PT, Brismée, Jean-Michel, ScD, PT, James, C. Roger, PhD, Sizer, Phillip S., PhD, PT, Sawyer, Steven F., PhD, PT

“…Abstract Lewis NL, Brismée JM, James CR, Sizer PS, Sawyer SF. The effect of stretching on muscle responses and postural sway responses during computerized…”
Get full text

A phase 1b study of humanized KS-interleukin-2 (huKS-IL2) immunocytokine with cyclophosphamide in patients with EpCAM-positive advanced solid tumors by Connor, Joseph P, Cristea, Mihaela C, Lewis, Nancy L, Lewis, Lionel D, Komarnitsky, Philip B, Mattiacci, Maria R, Felder, Mildred, Stewart, Sarah, Harter, Josephine, Henslee-Downey, Jean, Kramer, Daniel, Neugebauer, Roland, Stupp, Roger

“…Humanized KS-interleukin-2 (huKS-IL2), an immunocytokine with specificity for epithelial cell adhesion molecule (EpCAM), has demonstrated favorable…”
Get full text

A Phase I, open-label, dose escalation study of afatinib, in a 3-week-on/1-week-off schedule in patients with advanced solid tumors by Marshall, John, Hwang, Jimmy, Eskens, Ferry A. L. M., Burger, Herman, Malik, Shakun, Uttenreuther-Fischer, Martina, Stopfer, Peter, Ould-Kaci, Mahmoud, Cohen, Roger B., Lewis, Nancy L

“…Summary Background A Phase I study to determine the maximum tolerated dose (MTD) and pharmacokinetics of afatinib (BIBW 2992), a novel irreversible ErbB Family…”
Get full text

A Phase I trial of the kinesin spindle protein (Eg5) inhibitor AZD4877 in patients with solid and lymphoid malignancies by Gerecitano, John F., Stephenson, Joe J., Lewis, Nancy L., Osmukhina, Anna, Li, Jianguo, Wu, Kaida, You, Zhiping, Huszar, Dennis, Skolnik, Jeffrey M., Schwartz, Gary K.

“…Summary Background This Phase I study assessed the safety and maximum tolerated dose (MTD) of the kinesin spindle protein inhibitor AZD4877 in patients with…”
Get full text

A Phase II Trial of the Proteasome Inhibitor Bortezomib in Patients With Advanced Biliary Tract Cancers by Denlinger, Crystal S, Meropol, Neal J, Li, Tianyu, Lewis, Nancy L, Engstrom, Paul F, Weiner, Louis M, Cheng, Jonathan D, Alpaugh, R. Katherine, Cooper, Harry, Wright, John J, Cohen, Steven J

“…Micro-Abstract Therapeutic options in advanced biliary tract cancers are limited. We evaluated bortezomib in 20 patients with advanced biliary tract cancers in…”
Get full text

Isolation and Characterization of Circulating Tumor Cells in Patients with Metastatic Colorectal Cancer by Cohen, Steven J., Alpaugh, R. Katherine, Gross, Steve, O'Hara, Shawn M., Smirnov, Denis A., Terstappen, Leon W.M.M., Allard, W. Jeffrey, Bilbee, Maryann, Cheng, Jonathan D., Hoffman, John P., Lewis, Nancy L., Pellegrino, Ann, Rogatko, André, Sigurdson, Elin, Wang, Hao, Watson, James C., Weiner, Louis M., Meropol, Neal J.

“…Development of targeted therapeutic agents in colorectal cancer (CRC) is impeded by the lack of a noninvasive surrogate of drug effect. This pilot study…”
Get full text

The platelet-derived growth factor receptor as a therapeutic target by Lewis, Nancy L

“…Several small molecule tyrosine kinase inhibitors that block the epidermal growth factor receptor and vascular endothelial growth factor receptor function are…”
Get full text

Short-term sertraline treatment suppresses sympathetic nervous system activity in healthy human subjects by Shores, Molly M, Pascualy, Marcella, Lewis, Nancy L, Flatness, David, Veith, Richard C

“…Increased sympathetic nervous system (SNS) activity has been associated with stress, major depression, aging, and several medical conditions. This study…”
Get full text

Phase I study of capecitabine and oxaliplatin in combination with the proteasome inhibitor bortezomib in patients with advanced solid tumors by Cohen, Steven J, Engstrom, Paul F, Lewis, Nancy L, Langer, Corey J, McLaughlin, Susan, Beard, Mary, Weiner, Louis M, Meropol, Neal J

“…The combination of capecitabine and oxaliplatin has clinical benefit in a variety of gastrointestinal malignancies. The proteasome inhibitor bortezomib…”
Get full text

Development of New Agents for the Treatment of Advanced Colorectal Cancer by Lewis, Nancy L., Meropol, Neal J.

“…During the past decade, there have been several significant advances in the treatment of metastatic colorectal cancer. These include the introduction of the…”
Get full text

Phase I and pharmacokinetic study of the farnesyltransferase inhibitor R115777 in combination with irinotecan in patients with advanced cancer by COHEN, Steven J, GALLO, James, PALMER, Peter A, WEINER, Louis M, MEROPOL, Neal J, LEWIS, Nancy L, ALPAUGH, R. Katherine, GENTNER, Louis, ROGATKO, André, YESLOW, Gwen, SCHOL, Jessie, VERHAEGHE, Tom, ZANNIKOS, Peter

“…R115777 is a selective, nonpeptidomimetic inhibitor of farnesyltransferase (FTase), an enzyme responsible for the post-translational modification of several…”
Get full text

Oral Fluoropyrimidines in Cancer Treatment by Lewis, Nancy L., Meropol, Neal J.

Get full text

Phase I and pharmacokinetic study of irinotecan in combination with raltitrexed by LEWIS, Nancy L, SCHER, Richard, MEROPOL, Neal J, GALLO, James M, ENGSTROM, Paul F, SZARKA, Christine E, LITWIN, Samuel, ADAMS, Andrea L, KILPATRICK, Deborah, BRADY, Diane, WEINER, Louis M

“…To determine the maximum tolerated dose (MTD) of raltitrexed when given with irinotecan and to evaluate the pharmacokinetics of these two agents when given in…”
Get full text

Phase I Pharmacologic and Biologic Study of Ramucirumab (IMC-1121B), a Fully Human Immunoglobulin G 1 Monoclonal Antibody Targeting the Vascular Endothelial Growth Factor Receptor-2 by Spratlin, Jennifer L., Cohen, Roger B., Eadens, Matthew, Gore, Lia, Camidge, D. Ross, Diab, Sami, Leong, Stephen, O'Bryant, Cindy, Chow, Laura Q.M., Serkova, Natalie J., Meropol, Neal J., Lewis, Nancy L., Chiorean, E. Gabriela, Fox, Floyd, Youssoufian, Hagop, Rowinsky, Eric K., Eckhardt, S. Gail

“…Purpose To evaluate the safety, maximum-tolerated dose (MTD), pharmacokinetics (PKs), pharmacodynamics, and preliminary anticancer activity of ramucirumab…”
Get full text

Occult primary by Ettinger, David S, Agulnik, Mark, Cristea, Mihaela, Eaton, Keith, Fidias, Panagiotis M, Gockerman, Jon P, Hameed, Omar, Handorf, Charles, Harris, Elizabeth I, Jacobs, Charlotte D, Javle, Milind, Khushalani, Nikhil I, Kvols, Larry, Lenzi, Renato, Lewis, Nancy L, Rashid, Asif, Saltz, Leonard, Shulman, Lawrence N, Zager, Jonathan S, Zhen, Weining

Get more information

Divorced Parents and Their Children: A Guide for Mental Health Professionals by Lewis, Nancy L.

Get full text